For faster clinical trials, researchers may use drug repositioning with FDA (United States Food and Drug Administration)-approved drugs that have a long history of clinical application and are easily used to target resistant cancer cells once they are identified to inhibit P-gp activity or target P-gp-overexpressing drug-resistant cancer cells [11,12,13]. The gene discussed is PGP; the disease is cancer.